SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 229.12 |
| Enterprise Value ($M) | 264.63 |
| Book Value ($M) | 319.26 |
| Book Value / Share | 5.66 |
| Price / Book | 0.72 |
| NCAV ($M) | 314.15 |
| NCAV / Share | 5.57 |
| Price / NCAV | 0.73 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.29 |
| Return on Assets (ROA) | -0.25 |
| Return on Equity (ROE) | -0.26 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 17.63 |
| Current Ratio | 17.63 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 337.25 |
| Assets | 342.36 |
| Liabilities | 23.10 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -111.56 |
| Net Income | -94.26 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -81.21 |
| Cash from Investing | -191.86 |
| Cash from Financing | 157.20 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 4.40 | -28.95 | |
| 13G/A | Fairmount Funds Management LLC | 9.90 | 0.02 | |
| 13G/A | Fmr Llc | 13.90 | -7.56 | |
| 13G/A | Integrated Core Strategies (us) Llc | 3.50 | -32.36 | |
| 13G | ForGrowth III PA B.V. | 5.10 | ||
| 13G | Vestal Point Capital, LP | 7.10 | ||
| 13G/A | Ra Capital Management, L.p. | 9.00 | 15.68 | |
| 13D/A | Perceptive Advisors Llc | 11.50 | 0.00 | |
| 13G/A | TCG Crossover GP II, LLC | 4.90 | -36.78 | |
| 13G/A | Vanguard Group Inc | 4.67 | 0.00 | |
| 13G | BlackRock, Inc. | 6.20 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 19,031 | 328,989 | 5.78 | |
| 51,593 | 474,340 | 10.88 | |
| 143,487 | 1,007,227 | 14.25 | |
| 43,823 | 273,022 | 16.05 | |
| 105,296 | 568,865 | 18.51 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ARCT – Arcturus Therapeutics Holdings Inc. | ARDX – Ardelyx, Inc. |
| ATAI – Atai Life Sciences N.V. | AUPH – Aurinia Pharmaceuticals Inc. |
| AURA – Aura Biosciences, Inc. |
Financial data and stock pages provided by
Fintel.io